Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape

被引：206

作者：

Restifo, NP ^{[1
]}

机构：

[1] NCI, NIH, Bethesda, MD 20892 USA

来源：

NATURE MEDICINE | 2000年 / 6卷 / 05期

关键词：

D O I：

10.1038/74955

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Based on early studies, it was hypothesized that expression of Fas ligand (FasL) by tumor cells enabled them to counterattack the immune system, and that transplant rejection could be prevented by expressing FasL on transplanted organs. More recent studies have indicated that the notion of FasL as a mediator of immune privilege needed to be reconsidered, and taught a valuable lesson about making broad conclusions based on small amounts of data.

引用

页码：493 / 495

页数：3

共 31 条

[1] Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts
Allison, J
Georgiou, HM
Strasser, A
Vaux, DL
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) : 3943 - 3947
[2] Gene transfer of Fas ligand induces tumor regression in vivo
Arai, H
Gordon, D
Nabel, EG
Nabel, GJ
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (25) : 13862 - 13867
[3] A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION
BELLGRAU, D
GOLD, D
SELAWRY, H
MOORE, J
FRANZUSOFF, A
DUKE, RC
[J]. NATURE, 1995, 377 (6550) : 630 - 632
[4] BELLGRAU D, 1998, NATURE, V394, P133
[5] T cell-tumor cell: a fatal interaction?
Chappell, DB
Restifo, NP
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 1998, 47 (02) : 65 - 71
[6] Chappell DB, 1999, CANCER RES, V59, P59
[7] Functional expression of Fas and Fas ligand on human gut lamina propria T lymphocytes - A potential role for the acidic sphingomyelinase pathway in normal immunoregulation
DeMaria, R
Boirivant, M
Cifone, MG
Roncaioli, P
Hahne, M
Tschopp, J
Pallone, F
Santoni, A
Testi, R
[J]. JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (02) : 316 - 322
[8] Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10
Ekmekcioglu, S
Okcu, MF
Colome-Grimmer, MI
Owen-Schaub, L
Buzaid, AC
Grimm, EA
[J]. MELANOMA RESEARCH, 1999, 9 (03) : 261 - 272
[9] FIEDLER P, 1998, SCIENCE, V279, pA2015
[10] Gastman BR, 1999, CANCER RES, V59, P5356

← 1 2 3 4 →